Navigating regulatory challenges for cell and gene therapy products in 2024 and beyond
Cell & Gene Therapy Products 2022 Keynote: Peter Marks, CBER, FDA
Advanced Topics Successful Development of Quality Cell and Gene Therapy Products
Recent CMC Guidance for Cellular and Gene Therapies: BIO-ASGCT CGT Science Series
FDA’s Efforts to Advance the Development and Approval of Cellular and Gene Therapies
New Insights in Pharmacology: Highlights from the BJP and BJCP
The FDA's Role in Gene Therapy
Webinar: Manufacturing Challenges Facing Cell and Gene Therapy
Cell and Gene Therapy: Advancing the Next Generation of Pharmaceuticals
75th Cellular, Tissue, and Gene Therapies Advisory Committee
Development Advice for Gene Therapy Products
MEDIA CALL: FDA Approves First Gene Therapies to Treat Sickle Cell Disease – 12/08/2023
The Science Behind Gene Therapy
An Update on the Office of Cellular, Tissue and Gene Therapies: Celia Witten, FDA
Regulatory considerations for Cell and Gene Therapies - Jim DeKloe
76th Cellular, Tissue, and Gene Therapies Advisory Committee
Flexible manufacturing strategies for cell and gene therapy products
Meeting Regulatory Requirements for Cell and Gene Therapy Manufacturing
FDA Regulation of Cell and Gene Therapies: Facilitating Advanced Manufacturing
The Promises and Pitfalls of Gene Therapy for Rare Diseases
